0000000000441396

AUTHOR

Eva J. Ulbrich

showing 2 related works from this author

Transforming Growth Factor Beta 1 Serum Levels in Patients with Preinvasive and Invasive Lesions of the Breast

2004

Transforming growth factor beta (TGF-beta)1 is thought to be involved in breast carcinogenesis. TGF-beta1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-beta1 in breast cancer. We investigated TGF-beta1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-beta1 seru…

AdultOncology0301 basic medicinemedicine.medical_specialtyPathologyCancer ResearchMammary glandClinical BiochemistryCA 15-3Breast NeoplasmsPathology and Forensic MedicineTransforming Growth Factor beta103 medical and health sciencesBreast cancer0302 clinical medicineTransforming Growth Factor betaInternal medicinemedicineHumansNeoplasm Invasivenessskin and connective tissue diseasesEstrogen Receptor StatusAgedNeoplasm StagingAged 80 and overPredictive markerbusiness.industryMiddle AgedDuctal carcinomamedicine.diseaseFibroadenomamedicine.anatomical_structure030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisbusinessThe International Journal of Biological Markers
researchProduct

Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer

2003

The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median (range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425)…

AdultOncologymedicine.medical_specialtyCA 15-3Breast NeoplasmsBreast DiseasesBreast cancerReference ValuesInternal medicineBiomarkers TumormedicineCarcinomaHumansNeoplasm Invasivenessskin and connective tissue diseasesLymph nodeChemokine CCL2AgedRetrospective StudiesPredictive markerbusiness.industryCase-control studyGeneral MedicineMiddle AgedDuctal carcinomamedicine.diseaseCarcinoma Intraductal NoninfiltratingCell Transformation NeoplasticPhenotypemedicine.anatomical_structureCase-Control StudiesLymphatic MetastasisFemaleBreast carcinomabusinessTumor Biology
researchProduct